<!DOCTYPE html>
<html lang="en">
<head><!-- Google Tag Manager --> <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-N4XZHNC');</script> <!-- End Google Tag Manager -->

<title>GnRH Antagonists Relugolix and Degarelix: Mechanism and Side Effects</title>
  <meta charset="utf-8">
  
  <link href="urology2.css" rel="stylesheet">

<meta name="keywords" content="gnrh antagonists, degarelix, abarelix" >
<meta name="description" content="Pharmacological profile of GnRH antagonists abarelix , relugolix and degarelix to treat advanced prostate cancer...., from the online textbook of urology by D. Manski" >
<meta name="author" content="Dr. med. Dirk Manski" >
<meta name="copyright" content="Dirk Manski" >
<meta name="robots" content="index">
<meta name="robots" content="follow">
<meta name="viewport" content="width=device-width, initial-scale=1">
 </head>

<body><!-- Google Tag Manager (noscript) --> <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-N4XZHNC" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript> <!-- End Google Tag Manager (noscript) --> 
<header>
    <a class="ribbon" tabindex="-1" title="back to start!" href="https://www.urology-textbook.com/index.html">
	   <p><big>Urology-Textbook.com</big><br>
       <br>
       <small>Up-to-date urology insights from Dirk Manski</small></p>
    </a>  
</header>
<main> 
<article>
<nav role="navigation">
<div id="menuToggle">
<input type="checkbox" id="menuCheckbox" />
     <span></span>
    <span></span>
    <span></span>
<ul id="menu">
<li>
        <a href="https://www.urology-textbook.com/anatomy.html">
          <label for="menuCheckbox" onclick="this.parentNode.click();">Anatomy</label>
        </a>
      </li>
<li><a href="https://www.urology-textbook.com/signs-and-symptoms.html">Signs and Symptoms</a></li>
<li><a href="https://www.urology-textbook.com/examinations.html">Examinations</a></li>
<li><a href="https://www.urology-textbook.com/surgical-management.html">Surgical Management</a></li>
<li><a href="https://www.urology-textbook.com/pharmacology.html">Pharmacology</a></li>
<li><a href="https://www.urology-textbook.com/kidneys.html">Kidneys</a></li>
<li><a href="https://www.urology-textbook.com/ureters.html">Ureters</a></li>
<li><a href="https://www.urology-textbook.com/bladder.html">Bladder</a></li>
<li><a href="https://www.urology-textbook.com/prostate.html">Prostate</a></li>
<li><a href="https://www.urology-textbook.com/urethra.html">Urethra</a></li>
<li><a href="https://www.urology-textbook.com/penis.html">Penis</a></li>
<li><a href="https://www.urology-textbook.com/testes.html">Testes</a></li>
<li><a href="https://www.urology-textbook.com/adrenal-glands.html">Adrenal Glands</a></li>
<li><a href="https://www.urology-textbook.com/common-diseases.html">Common Diseases</a></li>
<li><a href="https://www.urology-textbook.com/urologic-surgery.html">Urologic Surgery</a></li>
<li><a href="https://www.urology-textbook.com/index-urology.html">Index</a></li>
<li><a href="https://www.urology-textbook.com/medical-abbreviations.html">Abbreviations</a></li>
<li><a href="https://www.urology-textbook.com/urology-news.html">News</a></li>
<li><a href="https://www.urology-textbook.com/links.html">Links</a></li>
</ul>



 
</div>
</nav>

<p id="brotkrumen">&nbsp;You are here: <a href="https://www.urology-textbook.com/index.html">Urology Textbook</a> &gt; <a href="https://www.urology-textbook.com/pharmacology.html">Drugs in Urology</a> &gt; GnRH antagonists</p>

<h1>GnRH Antagonists Relugolix and Degarelix: Mechanism and Side Effects</h1>

<p>Currently approved GnRH antagonists for the treatment of advanced <a href="https://www.urology-textbook.com/prostate-cancer.html">prostate cancer</a> are degarelix (approved in Germany 2009) and the orally available drug Relugolix (approved in the USA in 2020 and in Europe in 2023). Other formulations are under development or used in assisted fertilization, such as Cetrorelix and Ganirelix. Abarelix was withdrawn from the market due to side effects.</p>

<h2>Mechanism of Action of GnRH Antagonists </h2> 
<p>Gonadotropin-releasing hormone antagonists bind to the GnRH receptor without activation, they stop secretion of <a href="https://www.urology-textbook.com/male-hormones-testosterone.html#androgens">LH and FSH</a> with a dramatic reduction of the <a href="https://www.urology-textbook.com/testosterone-serum-test.html">testosterone concentration</a>. </p>

<h2>Indications for GnRH antagonists</h2> 
<p>Relugolix and degarelix are used for <a href="https://www.urology-textbook.com/prostate-cancer-hormonal-therapy.html">hormone therapy of advanced or metastatic prostate cancer</a>, as an alternative to surgical castration or treatment with GnRH analogs. The advantage of GnRH antagonists is an immediate, fast and reliable decrease in serum testosterone concentration (usually below 0.2 ng/ml). A short-term increase in testosterone, which is typical for GnRH analogs, does not occur. Thus, GnRH antagonists are ideal in patients who are at risk by a testosterone surge (e.g., symptomatic bone metastases with spinal cord compression). Disadvantages of GnRH antagonists is the limited data on long term safety, particularly concerning the immediate type allergic reaction or the cardiac side effects. </p>

<h2>Pharmacokinetics of Relugolix and Degarelix</h2>

<h3>Degarelix: </h3>
<p>Degarelix is a synthetic peptide derivative of the natural GnRH, which is administed as a subcutaneous depot preparation. After treatment with degarelix, 99% of patients reach castration level within 7 days (<a href="#Klotz2008">Klotz et al., 2008</a>). </p>

<h3>Relugolix: </h3>
<p>Oral administration, half-time 25 hours, 98% of patients reach castration level within 14 days (Shore et al., 2020).</p>

<h2>Side Effects of GnRH Antagonists </h2>

<p>GnRH antagonists cause a <a href="https://www.urology-textbook.com/male-hypogonadism.html">pronounced hypogonadism</a> with the following side effects (similar to GnRH agonist or surgical castration): osteoporosis, hot flashes, decreased libido, <a href="https://www.urology-textbook.com/erectile-dysfunction.html">loss of erectile function</a>, impaired memory function, physical weakness, fatigue, depression, increased cardiovascular risk, elevated transaminases and <a href="https://www.urology-textbook.com/gynecomastia.html">gynecomastia</a>. </p><h3>Further Side Effects:</h3>

<ul>
<li>Systemic allergic reactions of the immediate-type after injection of degarelix: urticaria, pruritus, hypotension and syncope. Degarelix is reported to cause significantly less allergic side effects compared to abarelix. 
</li>
<li>Prolongation of the QT interval or elevated liver enzymes are mainly caused by hypogonadism. In the pivotal trial of Relugolix, however, the risk of relevant cardiovascular events was halved compared to leuprorelin (Shore et al., 2020).</li>
</ul>

<h3>Specific side effects of degarelix: </h3>

<ul title="side effects of degarelix">
<li>Allergic reactions: degarelix is reported to cause significantly less allergic side effects compared to abarelix.
</li>
</ul><h2>Contraindications of Degarelix and Abarelix</h2>

<ul title="contraindications of degarelix and abarelix">
<li>GnRH antagonists are contraindicated (and useless) after surgical castration. </li>
<li>Children and Women</li>
<li>Severe allergic reactions after injection. </li>
<li>QT interval exceeding 450 msec. </li>
<li>Persistently increased transaminase concentrations (twice of the standard value).</li>
<li>Hepatic and renal insufficiency. </li>
</ul>

<h2>Dosage of Degarelix: </h2> 
<p>Subcutaneous injection of 2 × 120 mg degarelix at day 1 (two injections), followed by 80 mg s.c. every 4 weeks. Monitoring of therapy sucess: testosterone and PSA concentration.</p>

<h2>Dosage of Relugolix:</h2>
<p>360 mg orally as a starting dose, then 120 mg daily.</p>
<br>
<br>

<div id="ad-footer">
<!-- ad-footer -->
<ins class="adsbygoogle"
     style="display:inline-block;width:500px;height:250px"
     data-ad-client="ca-pub-9284927104423861"
     data-ad-slot="8746163219"></ins>
 <script>
     (adsbygoogle = window.adsbygoogle || []).push({});
</script>
</div>
<br><table id="navigation_unten">
<tr>
 
<td><a href="https://www.urology-textbook.com/gnrh-agonists.html">GnRH agonists</a></td>
<td><a class="nav4" href="https://www.urology-textbook.com/index-urology.html">Index</a></td>
<td><a class="nav3" href="https://www.urology-textbook.com/abiraterone.html">Abiraterone</a></td>
 
</tr>
</table>

<br>
<br>
Index: <a href="https://www.urology-textbook.com/index-urology-a.html">1&ndash;9</a> <a href="https://www.urology-textbook.com/index-urology-a.html">A</a> <a href="https://www.urology-textbook.com/index-urology-b.html">B</a> <a href="https://www.urology-textbook.com/index-urology-c.html">C</a> <a href="https://www.urology-textbook.com/index-urology-d.html">D</a> <a href="https://www.urology-textbook.com/index-urology-e.html">E</a> <a href="https://www.urology-textbook.com/index-urology-f.html">F</a> <a href="https://www.urology-textbook.com/index-urology-g.html">G</a> <a href="https://www.urology-textbook.com/index-urology-h.html">H</a> <a href="https://www.urology-textbook.com/index-urology-i.html">I</a> <a href="https://www.urology-textbook.com/index-urology-j.html">J</a> <a href="https://www.urology-textbook.com/index-urology-k.html">K</a> <a href="https://www.urology-textbook.com/index-urology-l.html">L</a> <a href="https://www.urology-textbook.com/index-urology-m.html">M</a> <a href="https://www.urology-textbook.com/index-urology-n.html">N</a> <a href="https://www.urology-textbook.com/index-urology-o.html">O</a> <a href="https://www.urology-textbook.com/index-urology-p.html">P</a> <a href="https://www.urology-textbook.com/index-urology-q.html">Q</a> <a href="https://www.urology-textbook.com/index-urology-r.html">R</a> <a href="https://www.urology-textbook.com/index-urology-s.html">S</a> <a href="https://www.urology-textbook.com/index-urology-t.html">T</a> <a href="https://www.urology-textbook.com/index-urology-u.html">U</a> <a href="https://www.urology-textbook.com/index-urology-v.html">V</a> <a href="https://www.urology-textbook.com/index-urology-w.html">W</a> <a href="https://www.urology-textbook.com/index-urology-xyz.html">X Y Z</a> 

<br>
<br>
<h3>References</h3>

<p>
<a NAME="Debruyne2006">
Debruyne u.a. 2006 D<SMALL>EBRUYNE</SMALL>, Frans&nbsp;; B<SMALL>HAT</SMALL>,
  Gajanan&nbsp;; G<SMALL>ARNICK</SMALL>, Marc&nbsp;B.:
</a>
 Abarelix for injectable suspension: first-in-class
  gonadotropin-releasing hormone antagonist for prostate cancer.
<br> In: <I>Future Oncol</I>
<br> 2 (2006), Dec, Nr.&nbsp;6, S.&nbsp;677&ndash;696. -
<br> URL <TT>http://dx.doi.org/10.2217/14796694.2.6.677</TT>
    </p>
<p>
<a NAME="Klotz2008">
Klotz u.a. 2008 K<SMALL>LOTZ</SMALL>, L.&nbsp;; B<SMALL>OCCON-</SMALL>G<SMALL>IBOD</SMALL>, L.&nbsp;;
  S<SMALL>HORE</SMALL>, N.&nbsp;D.&nbsp;; A<SMALL>NDREOU</SMALL>, C.&nbsp;; P<SMALL>ERSSON</SMALL>, B.-E.&nbsp;;
  C<SMALL>ANTOR</SMALL>, P.&nbsp;; J<SMALL>ENSEN</SMALL>, J.-K.&nbsp;; O<SMALL>LESEN</SMALL>, T.&nbsp;K.&nbsp;;
  S<SMALL>CHR&ouml;DER</SMALL>, F.&nbsp;H.:
</a>
 The efficacy and safety of degarelix: a 12-month, comparative,
  randomized, open-label, parallel-group phase III study in patients with
  prostate cancer.
<br> In: <I>BJU Int</I>
<br> 102 (2008), Dec, Nr.&nbsp;11, S.&nbsp;1531&ndash;1538. -
<br> URL <TT>http://dx.doi.org/10.1111/j.1464&ndash;410X.2008.08183.x</TT>
    </p>

<p>N. D. Shore <i>et al.</i>, “Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.,” <i>NEJM</i>, vol. 382, no. 23, pp. 2187–2196, 2020.</p>

<p>
<a NAME="Trachtenberg2002">
Trachtenberg u.a. 2002 T<SMALL>RACHTENBERG</SMALL>, J.&nbsp;;
  G<SMALL>ITTLEMAN</SMALL>, M.&nbsp;; S<SMALL>TEIDLE</SMALL>, C&nbsp;; B<SMALL>ARZELL</SMALL>, W.&nbsp;;
  F<SMALL>RIEDEL</SMALL>, W.&nbsp;; P<SMALL>ESSIS</SMALL>, D.&nbsp;; F<SMALL>OTHERINGHAM</SMALL>, N.&nbsp;;
  C<SMALL>AMPION</SMALL>, M.&nbsp;; G<SMALL>ARNICK</SMALL>, M.&nbsp;B.&nbsp;; G<SMALL>ROUP</SMALL>, Abarelix&nbsp;S.:
</a>
 A phase 3, multicenter, open label, randomized st.udy of abarelix
  versus leuprolide plus daily antiandrogen in men with prostate cancer.
<br> In: <I>J Urol</I>
<br> 167 (2002), Apr, Nr.&nbsp;4, S.&nbsp;1670&ndash;1674


<br>
<br>
<p><img src="https://images0.urology-textbook.com/deutsch.gif">&nbsp; Deutsche Version: <a href="https://www.urologielehrbuch.de/lhrh_antagonisten.html">GnRH Antagonisten</a></p>
</article>
</main>
<footer class="grid">
    <ul id="footer-nav">
    		<li>Copyright by Dr. med. Dirk Manski </li>
		<li><a href="https://www.urology-textbook.com/privacy-policy.html">Privacy policy</a></li>
		<li><a href="https://www.urology-textbook.com/disclaimer.html">Disclaimer</a></li>
	</ul>
	<a class="steady-login-button" data-size="medium" data-language="en" style="display: none;"></a>
</footer>
</body>
</html>
